© 2004-2012 Horse Tack Review
Horse Health Press Release
Intervet Inc., one of the world's leading
animal-health companies, announces the availability of Prodigy® with Havlogen® as an aid in the prevention of abortion and respiratory disease caused by Equine Herpesvirus 1 (EHV-1) infection found in horses. EHV-1 is the leading cause of infectious viral abortions in mares.
"EHV-1 is capable of causing respiratory disease, abortion, still births, fatal neonatal illness, and neurologic disease in infected horses. EHV-1 is very widespread in the horse population, and it is naturally spread most often from nasal secretions. However, the virus also can be carried and spread in fetal tissues, the placenta, and uterine fluids from mares that have aborted," says Craig Barnett, D.V.M., Intervet Technical Services Equine Veterinarian. "Horses exhibit only short-term protection following recovery from EHV-1 infection, and horses may be reinfected many times throughout their lives. Regular vaccination, along with sound management practices, can significantly decrease viral shedding and the incidence of abortion in the event of exposure."
EHV-1 routinely causes upper respiratory infection in young horses. Clinical signs include depression, poor appetite, nasal discharge and cough. In its most extreme form, EHV-1 can cause an outbreak of abortion, respiratory illness, and some neurologic diseases. Although the disease can be difficult to diagnose, Dr. Barnett says examination and laboratory tests performed by your veterinarian is the best way to determine if a horse is infected with EHV-1.
"Infected horses shed the virus to healthy horses primarily through respiratory secretions, for example, through direct nose-to-nose contact, coughing, or sneezing," says Barnett. "The healthier the horse, the better its chances are to ward off the attack of infection."
Prodigy vaccine provides superior protection against EHV-1
In a severe EHV-1 challenge study, Prodigy-vaccinated mares demonstrated
89.5 percent protection against abortions associated with EHV-1-induced infections and a
96.1 percent reduction in virus shedding from nasal exudates.
Prodigy is a killed virus vaccine, available in individually packaged one-dose syringes and 10-dose vials. For pregnant mares, administer a 2-mL dose intramuscularly during the fifth, seventh and ninth months of pregnancy. Three doses are essential for primary immunization. Maiden and barren mares housed or pastured with pregnant mares should be vaccinated on the same schedule. For primary immunization against respiratory disease administer three 2-mL doses intramuscularly at four- to six-week intervals. A 2-mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.
"Prodigy complements Intervet's existing portfolio of products, which address a host of respiratory, parasitic and reproductive issues," says Marv Jahde, Marketing Manager, Equine Products for Intervet. "Intervet products, such as Regu-Mate® (altrenogest), Panacur® (fenbendazole) POWERPAC, Flu Avert® I.N., Prestige® and Encevac® vaccines, are a testament to Intervet's commitment to keeping horses healthy and at peak performance."
For more information about Prodigy or other Intervet products, contact your veterinarian, contact Intervet Customer Service at 1-800-441-8272, or visit www.intervetusa.com.
Intervet Inc. (www.intervetusa.com) is an affiliate of Intervet International, one of the world's leading animal-health companies. The company is a leader in research and dedicated to the development, production and marketing of innovative, high-quality animal health products such as Regu-Mate® (altrenogest), Panacur® (fenbendazole) POWERPAC, Flu Avert® I.N., Prestige® and Encevac®. Intervet International employs more than 4,800 personnel and maintains a global distribution network of subsidiary companies and agents in 120 countries. Prodigy, Havlogen, Prestige, Regu-Mate, Safe-Guard, Panacur and Encevac are registered trademarks of Intervet Inc.